Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 11:19 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 549 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Irritability Clear all
Completed Phase 3 Interventional Results available

Rifaximin 3 Times/Day (TID) for Non-Constipation Irritable Bowel Syndrome (IBS)

NCT00724126
View directory record Official record
Conditions
Non-Constipation Irritable Bowel Syndrome
Interventions
Rifaximin, Placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
637 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
88
States / cities
Anniston, Alabama • Birmingham, Alabama • Huntsville, Alabama + 83 more
Source: ClinicalTrials.gov public record
Updated Nov 28, 2019 · Synced Jul 21, 2026, 11:19 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Assessing Symptom and Mood Dynamics in Pain Using the Smartphone Application SOMA

NCT05754190
View directory record Official record
Conditions
Chronic Pain, Acute Pain, Post Operative Pain, Fibromyalgia, Primary, Fibromyalgia, Secondary, Fibromyalgia, Irritable Bowel Syndrome, Chronic Headache Disorder, Chronic Migraine, Chronic Pelvic Pain Syndrome, Temporomandibular Joint Disorders, Endometriosis-related Pain, Arthritis, Chronic Low-back Pain, Failed Back Surgery Syndrome, Post Herpetic Neuralgia, Neuropathic Pain, Painful Diabetic Neuropathy, Painful Bladder Syndrome, Trauma-related Wound, Trauma, Multiple, Chronic Pain Syndrome, Chronic Shoulder Pain
Interventions
SOMA pain manager smartphone application
Device
Lead sponsor
Brown University
Other
Eligibility
18 Years and older
Enrollment
800 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Sep 18, 2025 · Synced Jul 21, 2026, 11:19 AM EDT
Recruiting Not applicable Interventional

Art Therapy and Emotional Well Being in Military Populations With Posttraumatic Stress Symptoms

NCT05414708
View directory record Official record
Conditions
PTSD, Military Activity, Post-Traumatic Headache, Posttraumatic Stress Disorder, Posttraumatic Stress Disorder, Delayed Onset, Sleep Disturbance, Nightmare, Irritable Mood, Anger, Combat and Operational Stress Reaction, Combat Stress Disorders, Military Family, Military Operations, Emotional Regulation, Emotion Processing
Interventions
Art Therapy
Behavioral
Lead sponsor
Walter Reed National Military Medical Center
Federal
Eligibility
18 Years to 64 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
2
States / cities
Bethesda, Maryland • Fort Belvoir, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Jul 21, 2026, 11:19 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Sorrel 25R Injector - Sorrel Clinical Study Protocol

NCT05221333
View directory record Official record
Conditions
Injection Site, Injection Site Reaction, Injection Site Irritation
Interventions
Sorrel Wearable Injector
Device
Lead sponsor
Eitan Medical
Industry
Eligibility
18 Years to 40 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 2, 2022 · Synced Jul 21, 2026, 11:19 AM EDT
Completed Phase 2 Interventional Results available

Characterization and Sequential Pharmacotherapy of Severe Mood Dysregulation

NCT01714310
View directory record Official record
Conditions
Severe Mood Dysregulation
Interventions
lisdexamfetamine, Placebo, fluoxetine
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
7 Years to 17 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 25, 2018 · Synced Jul 21, 2026, 11:19 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Safety Study to Investigate the Skin Irritancy Potential of Diclofenac-Menthol Gel

NCT02169154
View directory record Official record
Conditions
Pain
Interventions
1% Diclofenac Sodium, 3% Menthol, 0.09% Menthol, 0.2% Sodium Lauryl Sulfate, 0.9% Saline
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Paramus, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 28, 2017 · Synced Jul 21, 2026, 11:19 AM EDT
Completed Phase 2 Interventional

Efficacy, Safety and Tolerability of DNK333 (25 mg Bid) in Women With Diarrhea-predominant Irritable Bowel Syndrome (IBS-D)

NCT00394173
View directory record Official record
Conditions
Irritable Bowel Syndrome With Diarrhea (IBS-D)
Interventions
DNK333, Placebo
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
180 participants
Timeline
2006 – 2007
U.S. locations
37
States / cities
Tucson, Arizona • North Little Rock, Arkansas • Los Angeles, California + 34 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2017 · Synced Jul 21, 2026, 11:19 AM EDT
Completed Not applicable Interventional

Do Biomarkers Predict Response to a Pediatric Chronic Pain Symptom Management Program?

NCT03823742
View directory record Official record
Conditions
Irritable Bowel Syndrome, Functional Abdominal Pain Syndrome, Functional Gastrointestinal Disorders, Functional Bowel Disorder, Functional Abdominal Pain, Functional Abdominal Pain Disorders
Interventions
Cognitive Behavioral Therapy, Low FODMAP Diet
Other
Lead sponsor
Baylor College of Medicine
Other
Eligibility
7 Years to 12 Years
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Jul 21, 2026, 11:19 AM EDT
Terminated Phase 2 Interventional

Study of the Research Medicine CIN-103 in Adults With Irritable Bowel Syndrome With Predominant Diarrhea (IBS-D).

NCT06153420
View directory record Official record
Conditions
Irritable Bowel Syndrome With Diarrhea
Interventions
CIN-103, Placebo
Drug
Lead sponsor
CinPhloro Pharma, LLC
Industry
Eligibility
18 Years and older
Enrollment
421 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
53
States / cities
Dothan, Alabama • Huntsville, Alabama • Phoenix, Arizona + 45 more
Source: ClinicalTrials.gov public record
Updated Dec 14, 2025 · Synced Jul 21, 2026, 11:19 AM EDT
Terminated Phase 2 Interventional

Study to Evaluate the Effects of ONO-2952 on Pain Perception Produced by Rectal Distention in Female Subjects With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)

NCT01887002
View directory record Official record
Conditions
Irritable Bowel Syndrome (IBS)
Interventions
ONO-2952, Placebo comparator
Drug
Lead sponsor
Ono Pharma USA Inc
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
4
States / cities
Boston, Massachusetts • St Louis, Missouri • Chapel Hill, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2016 · Synced Jul 21, 2026, 11:19 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Pimavanserin for the Treatment of Irritability Associated With Autism Spectrum Disorder

NCT05523895
View directory record Official record
Conditions
Irritability Associated With Autism Spectrum Disorder
Interventions
Pimavanserin, Placebo
Drug
Lead sponsor
ACADIA Pharmaceuticals Inc.
Industry
Eligibility
5 Years to 17 Years
Enrollment
237 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
18
States / cities
Phoenix, Arizona • Glendale, California • San Rafael, California + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2025 · Synced Jul 21, 2026, 11:19 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study to Determine and Compare the Tolerance and Irritation Potential of Topical Acne Medications

NCT00964366
View directory record Official record
Conditions
Acne Vulgaris
Interventions
clindamycin and benzoyl peroxide, Dapsone gel
Drug
Lead sponsor
Stiefel, a GSK Company
Industry
Eligibility
18 Years to 45 Years
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Broomall, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 29, 2017 · Synced Jul 21, 2026, 11:19 AM EDT
Enrolling by invitation No phase listed Observational

Enabling Microbiomics- Driven Personalized Nutrition

NCT06657001
View directory record Official record
Conditions
Inflammatory Bowel Disease (IBD), Irritable Bowel Syndrome (IBS), Celiac Disease, Diarrhea, Constipation, Microbiome, Crohn's Disease, UC - Ulcerative Colitis, Microscopic Colitis, Functional Dyspepsia
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
4,001 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Jul 21, 2026, 11:19 AM EDT
Not yet recruiting No phase listed Observational

Psychotherapy for Irritability in Youth: Comparing Active Treatment to Nonactive Psychoeducation Supportive Psychotherapy

NCT07640802
View directory record Official record
Conditions
Irritability, Disruptive Mood Dysregulation Disorder, Oppositional Defiant Disorder, Attention Deficit Hyperactivity Disorder
Interventions
Psychotherapy
Behavioral
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
8 Years to 17 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2037
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Jul 21, 2026, 11:19 AM EDT
Completed Phase 2 Interventional Results available

Randomized, Double-blind, Dose-range-finding, Phase 2 Study of Linaclotide Administered to Patients With Irritable Bowel Syndrome With Constipation (IBS-C)

NCT00460811
View directory record Official record
Conditions
Irritable Bowel Syndrome With Constipation
Interventions
Linaclotide Acetate, Matching placebo
Drug
Lead sponsor
Ironwood Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
79
States / cities
Huntsville, Alabama • Chandler, Arizona • Tuscon, Arizona + 76 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2013 · Synced Jul 21, 2026, 11:19 AM EDT
Completed Not applicable Interventional

A Study of Hemp Hull WFI for IBS Diarrhea

NCT06028035
View directory record Official record
Conditions
Irritable Bowel Syndrome-bile Acid Diarrhea
Interventions
BB01
Dietary Supplement
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 70 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 4, 2024 · Synced Jul 21, 2026, 11:19 AM EDT
Not listed Not applicable Interventional

Cranial Electrotherapy Stimulation (CES) for Soldiers With Combat-Related Symptoms

NCT00866411
View directory record Official record
Conditions
Combat Related Symptoms, Irritability, Anger
Interventions
cranial electrotherapy stimulation (CES) with Alpha-Stim, placebo
Procedure
Lead sponsor
Brooke Army Medical Center
Federal
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
2
States / cities
Fort Hood, Texas • Fort Sam Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 19, 2009 · Synced Jul 21, 2026, 11:19 AM EDT
Terminated Phase 3 Interventional Results available

A Long-term Active Treatment Study of Mongersen (GED-0301) in Subjects With Crohn's Disease

NCT02641392
View directory record Official record
Conditions
Crohn's Disease
Interventions
GED-0301, Placebo
Drug · Other
Lead sponsor
Celgene
Industry
Eligibility
12 Years and older
Enrollment
310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
23
States / cities
San Diego, California • Atlanta, Georgia • Indianapolis, Indiana + 18 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2019 · Synced Jul 21, 2026, 11:19 AM EDT
Completed Phase 4 Interventional Results available

A Study of Different Use Regimens Using Two Acne Treatments

NCT00907257
View directory record Official record
Conditions
Acne Vulgaris
Interventions
benzoyl peroxide wash, Tretinoin gel
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
12 Years and older
Enrollment
247 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
12
States / cities
Boca Raton, Florida • Miami, Florida • Snellville, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2012 · Synced Jul 21, 2026, 11:19 AM EDT
Completed Phase 3 Interventional Results available

Second Plecanatide Study In Irritable Bowel Syndrome With Constipation (IBS-C)

NCT02493452
View directory record Official record
Conditions
Irritable Bowel Syndrome Characterized by Constipation
Interventions
Plecanatide, Placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
1,135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
191
States / cities
Birmingham, Alabama • Guntersville, Alabama • Huntsville, Alabama + 157 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2019 · Synced Jul 21, 2026, 11:19 AM EDT
Recruiting Phase 2 Interventional

A Study to Investigate Abdominal Symptoms With Camlipixant Compared With Placebo in Adults With Irritable Bowel Syndrome - Diarrhea (IBS-D) and Irritable Bowel Syndrome - Mixed (IBS-M)

NCT07519395
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Placebo, Camlipixant
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 80 Years
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
108
States / cities
Anniston, Alabama • Guntersville, Alabama • Mobile, Alabama + 88 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Jul 21, 2026, 11:19 AM EDT
Completed Phase 2 Interventional

Study to Assess the Efficacy and Safety of Rifaximin Administered BID in the Treatment of Patients With Diarrhea-Associated Irritable Bowel Syndrome

NCT00269412
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Rifaximin
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
525 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
67
States / cities
Scottsdale, Arizona • Tempe, Arizona • Anaheim, California + 61 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2019 · Synced Jul 21, 2026, 11:19 AM EDT
Completed Phase 2 Interventional

Diarrhea Predominant Irritable Bowel Syndrome in Females

NCT00461526
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
crofelemer
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
43
States / cities
Huntsville, Alabama • Chandler, Arizona • Tucson, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2019 · Synced Jul 21, 2026, 11:19 AM EDT
Completed Phase 2 Interventional

Phase 2 Study of MD-1100 Acetate on Gastrointestinal Transit in Patients With C-IBS

NCT00258193
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
MD-1100 Acetate
Drug
Lead sponsor
Ironwood Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 19, 2006 · Synced Jul 21, 2026, 11:19 AM EDT